



REVIEW

Open Access

Polymerase chain reaction–based assays for the diagnosis of human brucellosis

Ying Wang¹, Zhanli Wang¹, Yaxian Zhang¹, Liyun Bai¹, Yue Zhao¹, Chunfang Liu¹, An Ma^{2*} and Hui Yu^{1*}

Abstract

Polymerase chain reaction (PCR) is an in vitro technique for the nucleic acid amplification, which is commonly used to diagnose infectious diseases. The use of PCR for pathogens detection, genotyping and quantification has some advantages, such as high sensitivity, high specificity, reproducibility and technical ease. Brucellosis is a common zoonosis caused by *Brucella* spp., which still remains as a major health problem in many developing countries around the world. The direct culture and immunohistochemistry can be used for detecting infection with *Brucella* spp. However, PCR has the potential to address limitations of these methods. PCR are now one of the most useful assays for the diagnosis in human brucellosis. The aim of this review was to summarize the main PCR techniques and their applications for diagnosis and follow-up of patients with brucellosis. Moreover, advantages or limitation of the different PCR methods as well as the evaluation of PCR results for treatment and follow-up of human brucellosis were also discussed.

Keywords: Polymerase chain reaction techniques, Human brucellosis, *Brucella* spp, Molecular diagnosis

Introduction

Brucellosis is a widespread zoonotic disease caused by members of genus *Brucella*. Its prevalence is more than 10 per 100 000 population in some endemic countries [1]. Transmission of brucellosis from animals to humans occurs mainly through direct contact with infected animals, ingestion of raw dairy products of animal origin, or consumption of infected meat from domestic livestock [2]. Human brucellosis may lead to a variety of clinical presentations, such as fever, sweating, chills, headache, malaise, myalgia and even arthralgia of the large joints [3]. The presentations and phases of the disease may be acute, sub-acute, chronic, relapsed, active or inactive. Antibiotic treatment of human brucellosis often results in high treatment failure and relapse rates. Because the clinical presentation is non-specific, laboratory testing is required for confirmation.

Brucella species are gram-negative, facultative intracellular bacteria, which lack capsules, flagellae, endospores or native plasmids [4]. Currently, the genus *Brucella* consists of ten species: *B. abortus*, *B. suis*, *B. ovis*, *B. melitensis*, *B. canis*, *B. neotomae*, *B. pinnipedialis*, *B. ceti*, *B. microti* and *B. inopinata* [5]. Four species of the

genus *Brucella* are pathogenic for humans, namely *B. melitensis*, *B. abortus*, *B. suis*, and *B. canis*. *B. melitensis* is considered as the most pathogenic species, followed by *B. suis*, whereas *B. abortus* is the mildest type of brucellosis. Additionally, *Brucella* isolates from marine mammals can cause human infections. DNA-DNA hybridization studies demonstrated that there are high degrees of genetic similarity of *Brucella* spp. [6].

At present, there are various assays for diagnosis of human brucellosis such as standard microbiological tests for the isolation of *Brucella* spp. from blood, tissue specimens, body fluids and bone marrow, serological tests for the detection of anti-*Brucella* spp. antibodies and molecular methods for the detection of *Brucella* spp. DNA [7]. The most commonly used methods for detection and segregation of *Brucella* spp. were culture techniques and serological tests (standard agglutination tube test, anti-human globulin test, Rose-Bengal test, mercaptan-based tests, enzyme-linked immunosorbent assay and brucellacapt) [8,9]. However, isolation of *Brucella* spp. is associated with a risk of laboratory-acquired infections and time consuming, and culture sampling sensitivity is often low, depending on the culture medium, *Brucella* species, disease stage and quantity of circulating bacteria. Serological tests seem to be more effective but can be unspecific due to cross reaction or subsensitive

* Correspondence: mxtisme@126.com; huiyu2008@hotmail.com

²Zhejiang Academy of Medical Sciences, Hangzhou 310013, China

¹Baotou Medical College, Baotou 014010, China

reactions in samples from areas with a low or subclinical prevalence of brucellosis [10]. The principles and the main applications of these methods have been well reviewed elsewhere [11].

To ensure effective brucellosis disease prevention and control, a fast and accurate identification method is necessary. Polymerase chain reaction (PCR) technique offers a sensitive and specific way of detecting *Brucella* spp. from peripheral blood and other tissues [12]. The first brucellosis PCR-based test was introduced by Fekete *et al.* in 1990 [13]. They successfully amplified a 635 bp fragment of a 43 kDa outer membrane protein gene from *B. abortus* strain 19. Several studies have reported that PCR is a very useful tool for the rapid diagnosis of acute brucellosis and a good marker for the posttreatment follow-up and the early detection of relapses [14,15]. Moreover, many studies have developed PCR-based assays to differentiate 10 *Brucella* species [16-18]. Up to data, PCR assays have been used in diagnosis of both animal brucellosis and human brucellosis [19]. To our current knowledge, at least 200 reports have been published dealing with various methods based on PCR for laboratory diagnosis of human brucellosis. This review article highlights various PCR-based methods for the clinical diagnosis of human brucellosis. The principles, advantages or limitation of the different methods are also being discussed together with examples of applications taken from the literatures.

Standard PCR

For the diagnosis of human brucellosis, a PCR assay with one pair of primers was developed, which amplifies the target genomic sequence of *Brucella* species. Primer pairs include the primers for sequences encoding 16S rRNA [20,21], outer membrane protein (omp2a, omp2b) [22-24], 31-kDa immunogenic *Brucella abortus* protein (BCSP 31) [25,26], 16S-23S ribosomal DNA interspace region [27] and insertion sequence (IS711) [28,29]. Studies showed that standard PCR appeared to be a more sensitive technique than microbiological methods, not only for the diagnosis of a first episode of infection, but also for the early detection of relapses [30-32]. Some research groups also assessed the performances of standard PCR as diagnostic tools for human brucellosis with respect to conventional methods. Their results showed that standard PCR is a promising diagnostic tool for patients with clinical signs and symptoms, and negative serological results, allowing an accurate and early diagnosis of human brucellosis [33,34].

The standard PCR is simple and efficient. However, efficiency of this method is dependent on the specificity of the primers. Different primer pairs have previously been published for *Brucella* spp. detection, and only a few of them have been used in human samples. Baddour

MM *et al.* compared sensitivity of 3 pairs of primers amplify 3 different fragments including a gene encoding BCSP 31 (B4/B5), a sequence 16S rRNA of *B. abortus* (F4/R2), and a gene encoding omp2 (JPF/JPR). The results showed that the sensitivity of the B4/B5 primer pair, JPF/JPR primer pair and F4/R2 primer pair was 98%, 88.4% and 53.1%, respectively [35]. Navarro *et al.* also compared PCR methods using these 3 pairs of primers as described above. Their results further indicated that the three primers assayed showed a difference in sensitivity by the presence of human genomic DNA [36]. Table 1 showed the efficiency of blood PCR assays using different primers.

In fact, blood samples are often used for the diagnosis of human brucellosis by the standard PCR [37]. Several factors were reported to affect PCR results in a blood specimen such as the high concentrations of leukocytes DNA and heme compounds [38]. Additionally, human genomic DNA affect the sensitivity of peripheral-blood PCR assay for the detection of *Brucella* DNA [36]. Zerva L *et al.* reported that serum samples should be used preferentially over whole blood for diagnosis of human brucellosis by PCR [39], but Mitka S *et al.* revealed that buffy coat and whole blood were the optimal specimens [14]. Moreover, sample volume used and efficient DNA extraction protocol are also the points of concern for the standard PCR to be used in routine laboratory testing for human brucellosis [34].

Real time PCR

Compared with the standard PCR, real-time PCR is a valuable technique in determining the quantification of nucleic acids in individual blood samples, as well as in automating the data. With the decreasing prices of real-time PCR thermocyclers and the reagents, many more people now have access to this technology to measure DNA copy number, mRNA expression levels and viral titers [40]. Recently, real-time PCR for the rapid detection and differentiation of *Brucella* species in clinical samples has recently been developed, targeting 16S-23S internal transcribed spacer region (ITS) and the genes coding omp25 and omp31 [41], BCSP 31 [42-44], and IS711 [45,46].

Real-time PCR seems to be highly reproducible, rapid, sensitive and specific. Additionally, this assay is easily standardized and minimises the risk of infection in laboratory workers. It is therefore a useful method for both the initial diagnosis of human brucellosis and the differentiation among inactive, seropositive, and active states. Queipo-Ortuño *et al.* reported that the sensitivities of a SYBR Green I LightCycler-based real-time PCR assay with serum samples was 93.3%, which is higher than 90% and 65% obtained by PCR-ELISA with whole blood samples and blood cultures, respectively [47]. This group further developed a LightCycler-based real-time PCR assay to

Table 1 Efficiency of blood PCR assays

Primer	Sequence	Target gene	Sensitivity	Specificity	Positive predictive value	Negative predictive value	Reference
B4	TGGCTCGGTTGCCAATATCAA	bcp31	100	100	100	98	14
B5	CGCGCTTGCCCTTCAGGTCTG						
JPF	GCGCTCAGGCTGCCGACGCAA	omp2	98	100	100	96.1	14
JPR	ACCAGCCATTGCGGTGCGTA						
P1	TGGAGGTCAGAAATGAAC	omp2	99	100	100	98	14
P2	GAGTGCGAAACGAGCGC						
26A	GCCCTGACATAACCCGCTT	bp26	98.5	100	100	97.1	14
26B	GAGCGTGACATTTGCCGATA						
F4	TCGAGCGCCCGCAAGGGG	16S	53.1	100	53.1	100	35
R2	AACCATAGTGCTCCACTAA	rRNA					

detect *Brucella* DNA in serum samples. This assay was found to be 91.9% sensitive and 95.4% specific when tested with 65 negative control samples and 62 serum samples from patients with active brucellosis [48].

Furthermore, Surucuoglu S *et al.* compared the TaqMan real time PCR technique to conventional methods using serum samples from patients with different clinical forms of brucellosis. The sensitivity, specificity, positive and negative predictive values of this PCR method were calculated as 88%, 100%, 100%, and 83%, respectively [49]. Alsayed Y *et al.* further investigated the potential of a combination of several tests (culture, ELISA and real-time PCR) to support the diagnosis in different clinical manifestations of brucellosis with peripheral blood samples. They found that if the agglutination test is negative, real-time PCR, and/or ELISA, and/or culture are recommended [50]. Moreover, using a panel of seven primer sets, Winchell JM *et al.* developed a real-time PCR method to differentiate members of the *Brucella* genus isolates, and has the potential to detect novel species [51]. Other studies also reported that real-time PCR allowed the rapid diagnosis of human brucellosis [52,53]. These results suggest that the high species specificity and selectivity of real-time PCR assay make it a useful tool for diagnosis of human brucellosis.

Just as standard PCR, efficiency of real-time PCR is also dependent on the specificity of the primers. Kattar MM *et al.* developed three real-time PCRs for diagnosis of human brucellosis at genus level with hybridization probes and primers from *16S-23S ITS*, *omp25* and *omp31*. Their results showed that real-time PCR with *16S-23S ITS* primers and its probes was the most sensitive, indicating its potential for the diagnosis of human brucellosis in the clinical laboratory [41]. Additionally, a study analyzed the sensitivity and specificity of the 3 established real-time PCR methods using primers and TaqMan probes targeting the *IS711*, *bcp31* and *per* genes, and it also compared their efficiencies for the detection of the *Brucella* genus.

The results showed that the *IS711*-based real-time PCR was the most sensitive, specific and efficient to detect *Brucella* spp. [54]. Table 2 showed that the sensitivity of the *IS711* target was identical or 10 times higher than the sensitivity of the two other targets [54]. Moreover, the influences of other factors involved in the efficiency of the amplification process of real-time PCR for the diagnosis of human brucellosis were also reported, such as immunoglobulin G, which were extracted with the template DNA from serum samples [55].

Multiplex PCR

To overcome the inherent disadvantage of cost of the test, multiplex PCR has been developed to detect viral, bacterial, and/or other infectious agents. The advantages of using multiplex PCR technique are that it minimizes expense and recognizes many pathogens at once [56]. These advances have resulted in the appearance of numerous publications regarding the application of multiplex PCR in the diagnosis of human brucellosis.

Lübeck PS *et al.* developed and applied a multiplex PCR assay for *Brucella* diagnostics based on the peroxamine synthetase gene in 2003 [57]. El Kholly AA *et al.* also established a multiplex PCR technique using 2 sets of primers (B4/B5 and JPF/JPR) for the diagnosis of active human brucellosis in Egypt [58]. They found that this technique showed high sensitivity, specificity and accuracy, and could serve as important alternatives to culture methods for diagnosis of human brucellosis. Additionally, a multiplex PCR assay can be used to simultaneously detect and type *Brucella* species present in clinical samples. In 2007, Imaoka K *et al.* developed a multiplex PCR procedure to identify four major species of the genus *Brucella* in one reaction tube. Four pairs of primers targeting *bcp31*, *omp2b*, *omp2a* and *omp31* genes were used. The specific amplification for each *Brucella* spp. examined in this study was achieved with these primers [59]. Other groups also reported robust and rapid multiplex PCR assays, which

Table 2 Comparison of conventional and real-time PCR assays lower limit of detection (fg)

Brucella	IS711 copy number	Conventional PCR			Real-time PCR		
		IS711	bcbp31	per	IS711	bcbp31	per
<i>B. canis</i> RM6/66	6	100	1000	1000	2	20	20
<i>B. abortus</i> 544	7	100	1000	1000	2	2	2
<i>B. melitensis</i> 16 M	7	1000	1000	1000	2	20	20
<i>B. ovis</i> 63/290	38	100	1000	1000	0.2	2	2

(This table was taken from ref. [54]).

were able to identify and differentiate currently recognised *Brucella* species in a single test of less than an hour and a half [60-65]. The timely and accurate information provided by this assay would be valuable to trace sources of infection and may help in rapid diagnosis of human brucellosis. Furthermore, several multiplex PCRs have been described for identification of *Brucella* partly at the biovar level using different primer combinations. A 19-primer multiplex PCR specifically identified *B. neotomae*, *B. pinipedialis*, *B. ceti*, and *B. microti* simultaneously. Also, this method was able to differentiate *B. abortus* biovars 1, 2, 4 from biovars 3, 5, 6, 9 [66]. A novel multiplex PCR assay for the rapid detection of *Brucella* genus at the species and at the biovar level has been described. The assay was shown to be ideal method for detection of *B. suis* at the biovar level and the differentiation of *B. suis*, *B. canis* and *B. microti* [67]. It is well known that only a few biovars of *Brucella* species are pathogenic for humans, hence rapid identification of *Brucella* genus at the biovar level is necessary. Moreover, several multiplex PCRs have been described for the simultaneous detection of *Mycobacterium tuberculosis* (*M. tuberculosis*) complex and *Brucella* spp., targeting the *IS711*, *bcbp31* and *omp2a* genes for the identification of *Brucella* spp. and the *IS6110*, *senX3-regX3* and *cfp31* genes for the detection of the *M. tuberculosis* complex [68-70]. The results showed that this technique was a practical approach for the differential diagnosis between extrapulmonary tuberculosis and complicated brucellosis.

The primer pairs have substantial effect on the multiplex PCR efficiency. The presence of more than one primer pair in the multiplex PCR increases risk for primer-dimers. Thus, nonspecific products may be obtained [71]. Ideally, all the primer pairs in a multiplex PCR should not only eliminate non-specific PCR products, but also enable similar amplification efficiencies for their respective target. Therefore, the multiplex PCR requires laborious optimization [72].

Nested and semi-nested PCR

The nested PCR means that two different pairs of PCR primers are used for a single locus. The first pair is an amplified sequence. The second pair of primers (nested primers) is complementary to the sequence amplified by the first pair primers and produces a second PCR product

that will be shorter than the first one [73]. Same as nested, semi-nested PCR has two different pairs of PCR primers, but the second pair of primers has one primer identical to the first pair [74]. The nested PCR and semi-nested PCR amplify only the specific sequences sought and are more specific than the standard PCR. Recently, nested PCR and semi-nested PCR assays were developed for identifying *Brucella* in samples of human blood and then to explore their clinical practice for the diagnosis of human brucellosis.

Two nested PCR assays have been applied for the diagnosis of human brucellosis in Kuwait. Two pairs of primers derived from *IS711* were used. The results showed that the use of nested primers gave increased sensitivity and higher specificity providing a better molecular diagnostic approach for human brucellosis [75,76]. Lin GZ *et al.* also reported a nested PCR for the laboratory diagnosis of human brucellosis [77]. Moreover, a semi-nested PCR for diagnosis of human brucellosis were developed and evaluated with whole blood. The primers were from *IS6501* and *bcbp31* genes [78]. We are now performing nested PCR combined with real-time PCR approach for the diagnosis of human brucellosis with the primers from *bcbp31* and *VirB11* genes. *B. abortus* and *B. melitensis* can be rapidly identified. The results have not been reported. According to the results, this assay was sensitive and could be used for the diagnosis of human brucellosis in the clinical laboratory.

However, the nested PCR and semi-nested PCR have some disadvantages. For example, the assays increased risk of primer dimerization and cross-react of PCR products. In addition, the nested PCR or semi-nested PCR will only identify a set of *Brucella* bacteria, not a single specific species.

Other PCR-based assays

In addition to standard PCR and its derivatives (nested and semi-nested, multiplex and real-time PCR), there are other significant PCR-based assays have been developed in the last years. Fekete *et al.* developed the arbitrarily primed polymerase chain reaction (AP-PCR) to distinguish 25 different *Brucella* strains according to the banding patterns of their amplified DNA on agarose gels. The degrees of relatedness among these strains of the genus *Brucella*

were revealed through the calculated similarity coefficients [79]. In 1994, AMOS PCR assays were used to identify vaccine strains from strains that cause infections based on the number and sizes of products amplified by PCR [80,81]. In 1996, Tcherneva *et al.* reported the REP-PCR as a promising fingerprinting method for the evaluation of *Brucella* outbreak [82]. Also, various PCR-RFLPs display sufficient polymorphism to distinguish *Brucella* species and biovars, and can serve as tools for diagnostic, epidemiological, taxonomic, and evolutionary studies [83]. In addition, Multiple-locus variable-number tandem-repeat assays (MLVA) were used to study the molecular epidemiological characterization of *Brucella* isolates from humans [84]. PCR methods have been used successfully to identify all *Brucella* species and most of the biovars, offering an improvement over conventional molecular genotyping methods [85,86]. Furthermore, Bruce-ladder multiplex PCR assay was evaluated using 625 *Brucella* strains. This method can differentiate in a single step all of the classical *Brucella* species, including strains from marine mammals and the S19, RB51, and Rev.1 vaccine strains [67]. Recently, the microfluidic Lab-on-Chip was also proposed as a rapid and specific detection method for the characterization of *Brucella* isolates [87,88].

PCR-based assays were shown to be valuable tools for detecting *Brucella* strains. PCR approaches have several advantages for the diagnosis of human brucellosis, such as speed, safety, high sensitivity and specificity [89]. This technique might be considered complementary to the traditional methods and followed up by serology and/or culture [90]. However, its disadvantages such as the higher cost, issues of quality control and quality assurance must be further evaluated on clinical samples before PCR can be used in routine laboratory testing for human brucellosis [9,91].

Evaluation of PCR results for treatment and follow-up of patients

Most patients with brucellosis suffer a relapse after receive the duration and combination of antibiotic therapy. Therefore, it is necessary to evaluate the progress towards therapeutic failure or relapse [50]. The conventional methods are difficult for the diagnosis of these relapses. Several previous studies reported the applications of PCR for the diagnosis of post treatment follow-up and relapses. Queipo-Ortuño MI *et al.* examined the usefulness of PCR assay in post treatment follow-up and relapse of patients with brucellosis. They showed positive PCR tests for the relapse as well as negative once the relapse treatment was completed [26,30]. Nimri LF obtained the positive PCR results in the relapse cases, indicating that the assay could be a useful tool to confirm a relapse in cases of a treated brucellosis [21]. Navarro E *et al.* also developed a real-time PCR assay to monitor the evolution

of *Brucella melitensis* DNA load in blood during therapy and post-therapy follow-up in patients with brucellosis. This assay showed 100% analytical sensitivity for both initial infections and relapses [92]. Moreover, Mitka S *et al.* showed that PCR assays were negative in all follow-up samples from patients who had completed a successful treatment and were positive in all follow-up samples from patients who had relapses in the first year after therapy, including the times of the relapses [14]. However, dead phagocytosed bacteria may present in the circulating mononuclear cells in certain patients who have concluded successful treatment. Because PCR cannot differentiate between DNA from live and dead organisms, therefore, the ability to amplify the DNA of *Brucella* DNA from dead or phagocytized cells should be considered when interpreting the results.

Conclusions

At present, PCR-based assays could allow rapid and more-sensitive identification of *Brucella* genus at the species and at the biovar level, compared with traditional techniques. The implementation of PCR-based assays into the clinical setting will likely improve therapeutic outcomes. However, PCR protocols lack standardization. As new methods for *Brucella* spp. identification and typing, PCR tests are still being developed and still await validation for use with clinical samples. For instance, the sensitivity and specificity of most PCR-based methods is associated with inhibitors in DNA samples such as EDTA, RNase or DNase, heme, heparin, phenol, and probably a host of other reagents. There is still a great deal of work required for standardization before any of these methods may be used in routine laboratory testing for brucellosis. Future studies should focus on the integration of these techniques into clinical decision making.

Competing interests

The authors declare no conflicts of interest.

Authors' contributions

HY have made substantial contributions to conception, design and interpretation of data; YW, ZW, YZ, LB, YZ, CL and AM have been involved in drafting the manuscript or revising it critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgments

This work was support in part by grants from the National Natural Science Foundation of China (No.81360242), Natural Science Foundation of Inner Mongolia Autonomous Region of China (No. 2014JQ04, No. 2014MS0808) and Scientific Research Fund in Universities of Inner Mongolia Autonomous Region (No. NJZY14528).

Received: 24 March 2014 Accepted: 9 July 2014

Published: 1 August 2014

References

1. Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O, Akdeniz H: Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. *Int J Infect Dis* 2010, **14**(6):e469–e478.

2. Minas M, Minas A, Gourgulianis K, Stournara A: **Epidemiological and clinical aspects of human brucellosis in Central Greece.** *Jpn J Infect Dis* 2007, **60**(6):362–366.
3. Fanni F, Shahbaznejad L, Pourakbari B, Mahmoudi S, Mamishi S: **Clinical manifestations, laboratory findings, and therapeutic regimen in hospitalized children with brucellosis in an Iranian Referral Children Medical Centre.** *J Health Popul Nutr* 2013, **31**(2):218–222.
4. Moreno E, Cloeckaert A, Moriyón I: ***Brucella* evolution and taxonomy.** *Vet Microbiol* 2002, **90**(1–4):209–227.
5. Galińska EM, Zagórski J: **Brucellosis in humans—etiology, diagnostics, clinical forms.** *Ann Agric Environ Med* 2013, **20**(2):233–238.
6. Tiller RV, Gee JE, Frace MA, Taylor TK, Setubal JC, Hoffmaster AR, De BK: **Characterization of novel *Brucella* strains originating from wild native rodent species in North Queensland, Australia.** *Appl Environ Microbiol* 2010, **76**(17):5837–5845.
7. Sakran W, Chazan B, Koren A: **Brucellosis: clinical presentation, diagnosis, complications and therapeutic options.** *Harefuah* 2006, **145**(11):836–840. 860.
8. Nielsen K, Yu WL: **Serological diagnosis of brucellosis.** *Prilozi* 2010, **31**(1):65–89.
9. Al Dahouk S, Nöckler K: **Implications of laboratory diagnosis on brucellosis therapy.** *Expert Rev Anti Infect Ther* 2011, **9**(7):833–845.
10. Pabuccuoglu O, Ecemis T, El S, Coskun A, Akcali S, Sanlidag T: **Evaluation of serological tests for diagnosis of brucellosis.** *Jpn J Infect Dis* 2011, **64**(4):272–276.
11. Araj GF: **Update on laboratory diagnosis of human brucellosis.** *Int J Antimicrob Agents* 2010, **36**(Suppl 1):S12–S17.
12. Bricker BJ: **PCR as a diagnostic tool for brucellosis.** *Vet Microbiol* 2002, **90**(1–4):435–446.
13. Fekete A, Bantle JA, Halling SM, Sanborn MR: **Preliminary development of a diagnostic test for *Brucella* using polymerase chain reaction.** *J Appl Bacteriol* 1990, **69**(2):216–227.
14. Mitka S, Anetakis C, Souliou E, Diza E, Kansouzidou A: **Evaluation of different PCR assays for early detection of acute and relapsing brucellosis in humans in comparison with conventional methods.** *J Clin Microbiol* 2007, **45**(4):1211–1218.
15. Al Ajlan HH, Ibrahim AS, Al Salamah AA: **Comparison of different PCR methods for detection of *Brucella* spp. in human blood samples.** *Pol J Microbiol* 2011, **60**(1):27–33.
16. Gopaul KK, Koylass MS, Smith CJ, Whatmore AM: **Rapid identification of *Brucella* isolates to the species level by real time PCR based single nucleotide polymorphism (SNP) analysis.** *BMC Microbiol* 2008, **8**:86.
17. López Goñi I, García Yoldi D, Marín CM, De Miguel MJ, Muñoz PM, Blasco JM, Jacques I, Grayon M, Cloeckaert A, Ferreira AC, Cardoso R, de Sá MI C, Walravens K, Albert D, Garin-Bastuji B: **Evaluation of a multiplex PCR assay (Bruce-ladder) for molecular typing of all *Brucella* species, including the vaccine strains.** *J Clin Microbiol* 2008, **46**(10):3484–3487.
18. Hinić V, Brodard I, Thomann A, Cvetnić Z, Makaya PV, Frey J, Abril C: **Novel identification and differentiation of *Brucella melitensis*, *B. abortus*, *B. suis*, *B. ovis*, *B. canis*, and *B. neotomae* suitable for both conventional and real-time PCR systems.** *J Microbiol Methods* 2008, **75**(2):375–378.
19. Yu WL, Nielsen K: **Review of detection of *Brucella* spp. by polymerase chain reaction.** *Croat Med J* 2010, **51**(4):306–313.
20. Romero C, Gamazo C, Pardo M, López-Goñi I: **Specific detection of *Brucella* DNA by PCR.** *J Clin Microbiol* 1995, **33**(3):615–617.
21. Nimri LF: **Diagnosis of recent and relapsed cases of human brucellosis by PCR assay.** *BMC Infect Dis* 2003, **3**:5.
22. Leal Klevezas DS, Martínez Vázquez IO, López Merino A, Martínez Soriano JP: **Single-step PCR for detection of *Brucella* spp. from blood and milk of infected animals.** *J Clin Microbiol* 1995, **33**(12):3087–3090.
23. Sifuentes-Rincón AM, Revol A, Barrera-Saldaña HA: **Detection and differentiation of the six *Brucella* species by polymerase chain reaction.** *Mol Med* 1997, **3**(11):734–739.
24. Bardenstein S, Mandelboim M, Ficht TA, Baum M, Banai M: **Identification of the *Brucella melitensis* vaccine strain Rev.1 in animals and humans in Israel by PCR analysis of the PstI site polymorphism of its omp2 gene.** *J Clin Microbiol* 2002, **40**(4):1475–1480.
25. Matar GM, Khneisser IA, Abdelnoor AM: **Rapid laboratory confirmation of human brucellosis by PCR analysis of a target sequence on the 31-kilodalton *Brucella* antigen DNA.** *J Clin Microbiol* 1996, **34**(2):477–478.
26. Queipo-Ortuño MI, Morata P, Ocoñ P, Manchado P, Colmenero JD: **Rapid diagnosis of human brucellosis by peripheral-blood PCR assay.** *J Clin Microbiol* 1997, **35**(11):2927–2930.
27. Fox KF, Fox A, Nagpal M, Steinberg P, Heroux K: **Identification of *Brucella* by ribosomal-spacer-region PCR and differentiation of *Brucella canis* from other *Brucella* spp. pathogenic for humans by carbohydrate profiles.** *J Clin Microbiol* 1998, **36**(11):3217–3222.
28. Cloeckaert A, Grayon M, Grepinet O: **An IS711 element downstream of the bp26 gene is a specific marker of *Brucella* spp. isolated from marine mammals.** *Clin Diagn Lab Immunol* 2000, **7**(5):835–839.
29. Elfaki MG, Uz-Zaman T, Al-Hokail AA, Nakeeb SM: **Detection of *Brucella* DNA in sera from patients with brucellosis by polymerase chain reaction.** *Diagn Microbiol Infect Dis* 2005, **53**(1):1–7.
30. Morata P, Queipo-Ortuño MI, Reguera JM, García-Ordoñez MA, Pichardo C, Colmenero JD: **Posttreatment follow-up of brucellosis by PCR assay.** *J Clin Microbiol* 1999, **37**(12):4163–4166.
31. Elfaki MG, Al-Hokail AA, Nakeeb SM, Al-Rabiah FA: **Evaluation of culture, tube agglutination, and PCR methods for the diagnosis of brucellosis in humans.** *Med Sci Monit* 2005, **11**(11):MT69–MT74.
32. Briones Lara E, Palacios Saucedo Gdel C, Martínez Vázquez IO, Morales Loredó A, Bilbao Chávez Ldel P: **Response to the treatment of brucellosis among children. Evaluation with Huddleson reaction and PCR.** *Rev Med Inst Mex Seguro Soc* 2007, **45**(6):615–622.
33. Asaad AM, Alqahtani JM: **Serological and molecular diagnosis of human brucellosis in Najran, Southwestern Saudi Arabia.** *J Infect Public Health* 2012, **5**(2):189–194.
34. Gemechu MY, Gill JP, Arora AK, Ghatak S, Singh DK: **Polymerase chain reaction (PCR) assay for rapid diagnosis and its role in prevention of human brucellosis in Punjab, India.** *Int J Prev Med* 2011, **2**(3):170–177.
35. Baddour MM, Alkhalifa DH: **Evaluation of three polymerase chain reaction techniques for detection of *Brucella* DNA in peripheral human blood.** *Can J Microbiol* 2008, **54**(5):352–357.
36. Navarro E, Escribano J, Fernández J, Solera J: **Comparison of three different PCR methods for detection of *Brucella* spp in human blood samples.** *FEMS Immunol Med Microbiol* 2002, **34**(2):147–151.
37. Navarro E, Fernandez JA, Escribano J, Solera J: **PCR assay for diagnosis of human brucellosis.** *J Clin Microbiol* 1999, **37**(5):1654–1655.
38. Morata P, Queipo-Ortuño MI, de Dios CJ: **Strategy for optimizing DNA amplification in a peripheral blood PCR assay used for diagnosis of human brucellosis.** *J Clin Microbiol* 1998, **36**(9):2443–2446.
39. Zerva L, Bourantas K, Mitka S, Kansouzidou A: **Serum is the preferred clinical specimen for diagnosis of human brucellosis by PCR.** *J Clin Microbiol* 2001, **39**(4):1661–1664.
40. Ginzinger DG: **Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream.** *Exp Hematol* 2002, **30**(6):503–512.
41. Kattar MM, Zalloua PA, Araj GF, Samaha-Kfoury J, Shbaklo H, Kanj SS, Khalife S, Deeb M: **Development and evaluation of real-time polymerase chain reaction assays on whole blood and paraffin-embedded tissues for rapid diagnosis of human brucellosis.** *Diagn Microbiol Infect Dis* 2007, **59**(1):23–32.
42. Colmenero JD, Queipo-Ortuño MI, Reguera JM, Baeza G, Salazar JA, Morata P: **Real time polymerase chain reaction: a new powerful tool for the diagnosis of neurobrucellosis.** *J Neurol Neurosurg Psychiatry* 2005, **76**(7):1025–1027.
43. Debeauumont C, Falconnet PA, Maurin M: **Real-time PCR for detection of *Brucella* spp. DNA in human serum samples.** *Eur J Clin Microbiol Infect Dis* 2005, **24**(12):842–845.
44. Queipo-Ortuño MI, Colmenero JD, Bravo MJ, García-Ordoñez MA, Morata P: **Usefulness of a quantitative real-time PCR assay using serum samples to discriminate between inactive, serologically positive and active human brucellosis.** *Clin Microbiol Infect* 2008, **14**(12):1128–1134.
45. Cerekci A, Kılıç S, Bayraktar M, Uyanık MH, Yaşar E, Esen B: **Comparison of conventional methods and real-time multiplex polymerase chain reaction for identification and typing of *Brucella* isolates of human origin.** *Mikrobiyol Bul* 2011, **45**(3):392–400.
46. Zhang B, Wear DJ, Stojadinovic A, Izadjjou M: **Sequential real-time PCR assays applied to identification of genomic signatures in formalin-fixed paraffin-embedded tissues: a case report about brucella-induced osteomyelitis.** *Mil Med* 2013, **178**(1):88–94.
47. Queipo-Ortuño MI, Colmenero JD, Baeza G, Morata P: **Comparison between LightCycler Real-Time Polymerase Chain Reaction (PCR) assay with serum and PCR-enzyme-linked immunosorbent assay with whole blood samples for the diagnosis of human brucellosis.** *Clin Infect Dis* 2005, **40**(2):260–264.

48. Queipo-Ortuño MI, Colmenero JD, Reguera JM, García-Ordoñez MA, Pachón ME, Gonzalez M, Morata P: **Rapid diagnosis of human brucellosis by SYBR Green I-based real-time PCR assay and melting curve analysis in serum samples.** *Clin Microbiol Infect* 2005, **11**(9):713–718.
49. Surucuoğlu S, El S, Ural S, Gazi H, Kurutepe S, Taskiran P, Yurtsever SG: **Evaluation of real-time PCR method for rapid diagnosis of brucellosis with different clinical manifestations.** *Pol J Microbiol* 2009, **58**(1):15–19.
50. Alsayed Y, Monem F: **Brucellosis laboratory tests in Syria: what are their diagnostic efficacies in different clinical manifestations?** *J Infect Dev Ctries* 2012, **6**(6):495–500.
51. Winchell JM, Wolff BJ, Tiller R, Bowen MD, Hoffmaster AR: **Rapid identification and discrimination of *Brucella* isolates by use of real-time PCR and high-resolution melt analysis.** *J Clin Microbiol* 2010, **48**(3):697–702.
52. Navarro-Martínez A, Navarro E, Castaño MJ, Solera J: **Rapid diagnosis of human brucellosis by quantitative real-time PCR: a case report of brucellar spondylitis.** *J Clin Microbiol* 2008, **46**(1):385–387.
53. Colmenero JD, Clavijo E, Morata P, Bravo MJ, Queipo-Ortuño MI: **Quantitative real-time polymerase chain reaction improves conventional microbiological diagnosis in an outbreak of brucellosis due to ingestion of unpasteurized goat cheese.** *Diagn Microbiol Infect Dis* 2011, **71**(3):294–296.
54. Bounaadja L, Albert D, Chenais B, Henault S, Zygmunt MS, Poliak S, Garin Bastuji B: **Real-time PCR for identification of *Brucella* spp.: a comparative study of IS711, bcsps31 and per target genes.** *Vet Microbiol* 2009, **137**(1–2):156–164.
55. Queipo-Ortuño MI, De Dios CJ, Macias M, Bravo MJ, Morata P: **Preparation of bacterial DNA template by boiling and effect of immunoglobulin G as an inhibitor in real-time PCR for serum samples from patients with brucellosis.** *Clin Vaccine Immunol* 2008, **15**(2):293–296.
56. Elnifro EM, Ashshi AM, Cooper RJ, Klapper PE: **Multiplex PCR: optimization and application in diagnostic virology.** *Clin Microbiol Rev* 2000, **13**(4):559–570.
57. Lübeck PS, Skurnik M, Ahrens P, Hoorfar J: **A multiplex PCR-detection assay for *Yersinia enterocolitica* serotype O:9 and *Brucella* spp. based on the perosamine synthetase gene. Application to *Brucella* diagnostics.** *Adv Exp Med Biol* 2003, **529**:451–453.
58. El Kholly AA, Gomaa HE, El Anany MG, Abd El Rasheed E: **Diagnosis of human brucellosis in Egypt by polymerase chain reaction.** *East Mediterr Health J* 2009, **15**(5):1068–1074.
59. Imaoka K, Kimura M, Suzuki M, Kamiyama T, Yamada A: **Simultaneous detection of the genus *Brucella* by combinatorial PCR.** *Jpn J Infect Dis* 2007, **60**(2–3):137–139.
60. Rees RK, Graves M, Caton N, Ely JM, Probert WS: **Single tube identification and strain typing of *Brucella melitensis* by multiplex PCR.** *J Microbiol Methods* 2009, **78**(1):66–70.
61. Mayer-Scholl A, Draeger A, Göllner C, Scholz HC, Nöckler K: **Advancement of a multiplex PCR for the differentiation of all currently described *Brucella* species.** *J Microbiol Methods* 2010, **80**(1):112–114.
62. Kumar S, Tuteja U, Sarika K, Singh D, Kumar A, Kumar O: **Rapid multiplex PCR assay for the simultaneous detection of the *Brucella* Genus, *B. abortus*, *B. melitensis*, and *B. suis*.** *J Microbiol Biotechnol* 2011, **21**(1):89–92.
63. Garofolo G, Ancora M, Di Giannatale E: **MLVA-16 loci panel on *Brucella* spp. using multiplex PCR and multicolor capillary electrophoresis.** *J Microbiol Methods* 2013, **92**(2):103–107.
64. Mirnejad R, Mohamadi M, Piranfar V, Mortazavi SM, Kachuei R: **A duplex PCR for rapid and simultaneous detection of *Brucella* spp. in human blood samples.** *Asian Pac J Trop Med* 2013, **6**(6):453–456.
65. Kamal IH, Al Gashgari B, Mosehly SS, Kumosani TA, Abulnaja KO: **Two-stage PCR assay for detection of human brucellosis in endemic areas.** *BMC Infect Dis* 2013, **13**:145.
66. Huber B, Scholz HC, Lucero N, Busse HJ: **Development of a PCR assay for typing and subtyping of *Brucella* species.** *Int J Med Microbiol* 2009, **299**(8):563–573.
67. López-Goñi I, García-Yoldi D, Marín CM, de Miguel MJ, Barquero-Calvo E, Guzmán-Verrí C, Albert D, Garin-Bastuji B: **New Bruce-ladder multiplex PCR assay for the biovar typing of *Brucella suis* and the discrimination of *Brucella suis* and *Brucella canis*.** *Vet Microbiol* 2011, **154**(1–2):152–155.
68. Queipo-Ortuño MI, Colmenero JD, Bermudez P, Bravo MJ, Morata P: **Rapid differential diagnosis between extrapulmonary tuberculosis and focal complications of brucellosis using a multiplex real-time PCR assay.** *PLoS One* 2009, **4**(2):e4526.
69. Colmenero JD, Morata P, Ruiz Mesa JD, Bautista D, Bermúdez P, Bravo MJ, Queipo Ortuño MI: **Multiplex real-time polymerase chain reaction: a practical approach for rapid diagnosis of tuberculous and brucellar vertebral osteomyelitis.** *Spine (Phila Pa 1976)* 2010, **35**(24):E1392–E1396.
70. Sanjuan Jimenez R, Colmenero JD, Bermúdez P, Alonso A, Morata P: **Amplicon DNA melting analysis for the simultaneous detection of *Brucella* spp and *Mycobacterium tuberculosis* complex. Potential use in rapid differential diagnosis between extrapulmonary tuberculosis and focal complications of brucellosis.** *PLoS One* 2013, **8**(3):e58353.
71. Brownie J, Shawcross S, Theaker J, Whitcombe D, Ferrie R, Newton C, Little S: **The elimination of primer-dimer accumulation in PCR.** *Nucleic Acids Res* 1997, **25**:3235–3241.
72. Cha RS, Thilly WG: **Specificity, efficiency, and fidelity of PCR.** *PCR Methods Appl* 1993, **3**:S18–S29.
73. Porter-Jordan K, Rosenberg EI, Keiser JF, Gross JD, Ross AM, Nasim S, Garrett CT: **Nested polymerase chain reaction assay for the detection of cytomegalovirus overcomes false positives caused by contamination with fragmented DNA.** *J Med Virol* 1990, **30**(2):85–91.
74. Seah CL, Chow VT, Chan YC: **Semi-nested PCR using NS3 primers for the detection and typing of dengue viruses in clinical serum specimens.** *Clin Diagn Virol* 1995, **4**(2):113–120.
75. Al Nakkas AF, Wright SG, Mustafa AS, Wilson S: **Single-tube, nested PCR for the diagnosis of human brucellosis in Kuwait.** *Ann Trop Med Parasitol* 2002, **96**(4):397–403.
76. Al-Nakkas A, Mustafa AS, Wright SG: **Large-scale evaluation of a single-tube nested PCR for the laboratory diagnosis of human brucellosis in Kuwait.** *J Med Microbiol* 2005, **54**(Pt 8):727–730.
77. Lin GZ, Zheng FY, Zhou JZ, Gong XW, Wang GH, Cao XA, Qiu CQ: **Loop-mediated isothermal amplification assay targeting the omp25 gene for rapid detection of *Brucella* spp.** *Mol Cell Probes* 2011, **25**(2–3):126–129.
78. Cirak MY, Hızal K: **The value of polymerase chain reaction methods targeting two different gene regions for the diagnosis of brucellosis.** *Mikrobiyol Bul* 2002, **36**(3–4):271–276.
79. Fekete A, Bantle JA, Halling SM, Stich RW: **Amplification fragment length polymorphism in *Brucella* strains by use of polymerase chain reaction with arbitrary primers.** *J Bacteriol* 1992, **174**(23):7778–7783.
80. Bricker BJ, Halling SM: **Enhancement of the *Brucella* AMOS PCR assay for differentiation of *Brucella abortus* vaccine strains S19 and RB51.** *J Clin Microbiol* 1995, **33**(6):1640–1642.
81. Bricker BJ, Halling SM: **Differentiation of *Brucella abortus* bv. 1, 2, and 4, *Brucella melitensis*, *Brucella ovis*, and *Brucella suis* bv. 1 by PCR.** *J Clin Microbiol* 1994, **32**(11):2660–2666.
82. Tcherneva E, Rijpens N, Naydensky C, Herman L: **Repetitive element sequence based polymerase chain reaction for typing of *Brucella* strains.** *Vet Microbiol* 1996, **51**(1–2):169–178.
83. Al Dahouk S, Tomaso H, Prenger-Berninghoff E, Spletstoeser WD, Scholz HC, Neubauer H: **Identification of *brucella* species and biotypes using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).** *Crit Rev Microbiol* 2005, **31**(4):191–196.
84. Marianelli C, Graziani C, Santangelo C, Xibilia MT, Imbriani A, Amato R, Neri D, Cuccia M, Rinnone S, Di Marco V, Ciuchini F: **Molecular epidemiological and antibiotic susceptibility characterization of *Brucella* isolates from humans in Sicily, Italy.** *J Clin Microbiol* 2007, **45**(9):2923–2928.
85. Marianelli C, Ciuchini F, Tarantino M, Pasquali P, Adone R: **Molecular characterization of the rpoB gene in *Brucella* species: new potential molecular markers for genotyping.** *Microbes Infect* 2006, **8**(3):860–865.
86. Scholz HC, Tomaso H, Al Dahouk S, Witte A, Schloter M, Kämpfer P, Falsen E, Neubauer H: **Genotyping of *Ochrobactrum anthropi* by recA-based comparative sequence, PCR-RFLP, and 16S rRNA gene analysis.** *FEMS Microbiol Lett* 2006, **257**(1):7–16.
87. De Santis R, Ciammaruconi A, Faggioni G, Fillo S, Gentile B, Di Giannatale E, Ancora M, Lista F: **High throughput MLVA-16 typing for *Brucella* based on the microfluidics technology.** *BMC Microbiol* 2011, **11**:60.
88. De Santis R, Ciammaruconi A, Faggioni G, D'Amelio R, Marianelli C, Lista F: **Lab on a chip genotyping for *Brucella* spp. based on 15-loci multi locus VNTR analysis.** *BMC Microbiol* 2009, **9**:66.
89. Navarro E, Casao MA, Solera J: **Diagnosis of human brucellosis using PCR.** *Expert Rev Mol Diagn* 2004, **4**(1):115–123.
90. Al-Attas RA, Al-Khalifa M, Al-Qurashi AR, Badawy M, Al-Ghaly N: **Evaluation of PCR, culture and serology for the diagnosis of acute human brucellosis.** *Ann Saudi Med* 2000, **20**(3–4):224–228.

91. Al Dahouk S, Tomaso H, Nöckler K, Neubauer H, Frangoulidis D: **Laboratory-based diagnosis of brucellosis—a review of the literature. Part I: Techniques for direct detection and identification of *Brucella* spp.** *Clin Lab* 2003, **49**(9–10):487–505.
92. Navarro E, Segura JC, Castaño MJ, Solera J: **Use of real-time quantitative polymerase chain reaction to monitor the evolution of *Brucella melitensis* DNA load during therapy and post-therapy follow-up in patients with brucellosis.** *Clin Infect Dis* 2006, **42**(9):1266–1273.

doi:10.1186/s12941-014-0031-7

Cite this article as: Wang *et al.*: Polymerase chain reaction–based assays for the diagnosis of human brucellosis. *Annals of Clinical Microbiology and Antimicrobials* 2014 **13**:31.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

